       Document 0438
 DOCN  M9640438
 TI    Treatment of Kaposi's sarcoma with liposomal doxorubicin.
 DT    9604
 AU    Bergin C; O'Leary A; McCreary C; Sabra K; Mulcahy F; Department of
       Genitourinary Medicine, St. James's Hospital,; Dublin, Ireland.
 SO    Am J Health Syst Pharm. 1995 Sep 15;52(18):2001-4. Unique Identifier :
       AIDSLINE MED/96083884
 AB    The efficacy of liposomal doxorubicin for treating Kaposi's sarcoma (KS)
       in patients infected with human immunodeficiency virus (HIV) was
       studied. Eight men with HIV infection and KS were to be given liposomal
       doxorubicin 20 mg/sq m i.v. monthly for six months and 10 mg/sq m i.v.
       monthly thereafter, depending on the response. They were assessed for
       the onset, extent, and duration of clinical response; relapse; adverse
       effects; development of new opportunistic infections; quality of life;
       and survival. Five patients had a clinical complete response (i.e.,
       complete resolution of the manifestations of KS, as determined by
       physical examination but not confirmed by biopsy) and three patients had
       a partial response to the induction regimen of liposomal doxorubicin.
       Relapse occurred in all patients in whom therapy was stopped;
       reinstatement of therapy elicited a partial response. Neutropenia
       occurred in two patients; filgrastim therapy enabled the liposomal
       doxorubicin therapy to continue uninterrupted. Thromboembolic events
       developed or were suspected in three patients, although they may not
       have been caused by liposomal doxorubicin. Monthly i.v. administration
       of liposomal doxorubicin partially or completely eliminated the clinical
       manifestations of Kaposi's sarcoma in eight men infected with HIV.
 DE    Adult  Antibiotics, Anthracycline/ADVERSE EFFECTS/*THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/COMPLICATIONS  Doxorubicin/ADVERSE
       EFFECTS/*THERAPEUTIC USE  Drug Carriers  Homosexuality, Male  Human  HIV
       Infections/*COMPLICATIONS  Liposomes  Male  Middle Age  Sarcoma,
       Kaposi's/*DRUG THERAPY  Skin Neoplasms/*DRUG THERAPY  Treatment Outcome
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

